Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
64 hedge funds and large institutions have $48.1M invested in Marinus Pharmaceuticals, Inc in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 19 closing their positions.
162% more call options, than puts
Call options by funds: $1.52M | Put options by funds: $579K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
17% less funds holding
Funds holding: 77 → 64 (-13)
66% less capital invested
Capital invested by funds: $140M → $48.1M (-$92M)
68% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$6.97M |
| 2 |
VMI
VHCP Management III
New York
|
+$2.54M |
| 3 |
VMI
VHCP Management II
New York
|
+$1.5M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$404K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$257K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$17.6M |
| 2 |
Goldman Sachs
New York
|
-$3.53M |
| 3 |
O
OrbiMed
New York
|
-$1.65M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.5M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$1.12M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACH
76
ArrowMark Colorado Holdings
Denver,
Colorado
| – | -$45K | -2,684 | Closed |
|
|
SAMH
77
Shanda Asset Management Holdings
Tortola,,
British Virgin Islands
| – | -$42K | -2,500 | Closed |
|
78
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$26K | -1,575 | Closed |
|
|
PCM
79
Prelude Capital Management
New York
| – | -$2K | -125 | Closed |
|
|
TWA
80
TCI Wealth Advisors
Tucson,
Arizona
| – | -$202 | -25 | -50% |
|
|
AG
81
Advisor Group
Phoenix,
Arizona
| – | +$202 | +25 | +192% |
|
MRNS Hedge Fund Activity: Q3 2019 in Review
64 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2019, worth a combined $48.1M — down 66% from $140M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MRNS and 6 opened new positions — a net loss of 13 holders — while 22 trimmed existing stakes and 22 added.
The largest buyer was Lion Point Capital, opening a new position worth an estimated $6.97M. The largest seller was Jennison Associates, exiting entirely with an estimated $17.6M sold.
- 64 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2019, down from 77 in Q2 2019.
- Funds reported $48.1M of Marinus Pharmaceuticals, Inc stock for Q3 2019, down 66% quarter-over-quarter.
- 6 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2019 and 19 closed out, a net change of -13 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2019 was Lion Point Capital, an estimated $6.97M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2019 was Jennison Associates, an estimated $17.6M sold.
Based on aggregated 13F filings for Q3 2019.